Alzamend Neuro Files S-1/A Amendment
Ticker: ALZN · Form: S-1/A · Filed: Mar 27, 2025 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | S-1/A |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, registration-statement, pharmaceutical
TL;DR
Alzamend Neuro filed an S-1/A amendment, looks like they're still prepping for a stock offering.
AI Summary
Alzamend Neuro, Inc. filed an S-1/A amendment on March 27, 2025, for its registration statement. The company, incorporated in Delaware, is in the pharmaceutical preparations sector and is headquartered in Atlanta, GA. This filing is a pre-effective amendment to a Form S-3 on Form S-1, indicating ongoing efforts to register securities.
Why It Matters
This filing signifies Alzamend Neuro's continued efforts to register securities, which is a crucial step for potential public offerings or other capital-raising activities.
Risk Assessment
Risk Level: medium — S-1/A filings often precede significant corporate actions like stock offerings, which carry inherent market risks.
Key Numbers
- 333-285788 — SEC File Number (Identifies the specific registration filing)
- 2834 — SIC Code (Indicates the company operates in Pharmaceutical Preparations)
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- 333-285788 (dollar_amount) — SEC File Number
- March 27, 2025 (date) — Filing Date
- Stephan Jackman (person) — Chief Executive Officer
- Henry Nisser (person) — Executive Vice President and General Counsel
FAQ
What is the purpose of this S-1/A filing?
This filing is a pre-effective amendment to a Form S-3 on Form S-1, indicating Alzamend Neuro, Inc. is updating its registration statement for securities.
When was this amendment filed?
The amendment was filed with the SEC on March 27, 2025.
What industry does Alzamend Neuro, Inc. operate in?
Alzamend Neuro, Inc. operates in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
Who are the key executives mentioned in the filing?
Stephan Jackman is listed as Chief Executive Officer and Henry Nisser as Executive Vice President and General Counsel.
Where is Alzamend Neuro, Inc. headquartered?
The company's principal executive offices are located at 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on March 27, 2025 by Stephan Jackman regarding Alzamend Neuro, Inc. (ALZN).